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ABSTRACT
Objective: Various clinical trials have compared terlipressin and octreotide in the management of acute variceal bleed, but their results have been 
inconsistent. Therefore, the present meta-analysis was performed to compare the clinical efficacy and safety of terlipressin and octreotide and gather 
the strength of evidence regarding their use in variceal hemorrhage.
Methods: Randomized control trials were identified using PubMed search engine and Cochrane clinical trial register (from 1994 to 2019). Initial 
hemostasis rate, rebleeding rate on the 5th day, and overall mortality rate during the study period were studied. The extracted data were analyzed 
using review manager 5.3 software. Odds ratio with 95% confidence intervals (CI) was estimated for the dichotomous outcomes.
Results: A total of six randomized control trials were identified. Through comparisons of data for terlipressin and octreotide groups, we found 
no statistically significant differences in the initial hemostasis rate, rebleeding rate on the 5th day, and overall mortality rate between the different 
treatment approaches.
Conclusion: The comparison of terlipressin and octreotide showed them to be equally effective and safe therapeutic agents in patients of acute 
variceal bleeding. Further, evidence from the future randomized controlled trials with higher quality and larger sample sizes is needed to confirm 
these findings.
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INTRODUCTION
Acute variceal bleeding is an emergency condition where the 
patient may deteriorate suddenly and may succumb to death, if not 
appropriately managed. In spite of all the advances in medical science 
and technology, it still accounts for up to 20% mortality at 6 weeks [1]. 
The outcome of an episode of an active hemorrhage depends on the 
control of active bleeding and prevention of associated complications. 
The first step, in the management, is the initiation of pharmacologic 
therapy along with simultaneous hemodynamic resuscitation [2].
Pharmacological therapy typically consists of vasopressors. They 
contract the gastrointestinal blood vessels, thereby decreasing the 
blood flow to the portal vein. This reduces the portal venous pressure 
resulting in hemostasis. In addition to that, these agents also provide a 
clearer view of an endoscopic procedure, if needed.
Octreotide, a somatostatin analog, and terlipressin, a derivative 
of vasopressin, are commonly used as vasopressors. While 
octreotide causes only splanchnic vasoconstriction, terlipressin 
has dual effects both splanchnic and systemic vasoconstriction 
that may predispose to systemic adverse effects. It has been found 
that terlipressin decreases mortality rates in patients with acute 
variceal bleeding while there is a limited subset of data regarding 
efficacy of octreotide. These two classes of pharmacotherapy have 
been evaluated in several studies; but controversy exists regarding 
their overall risks and benefits [3,4]. Few meta-analyses have 
been conducted, but they have compared the vasoactive agents 
with interventions such as endoscopic procedure or band ligation. 
According to recent guidelines, these two modalities are used 
concurrently and this comparison does not reflect standard of 
care [5]. Few studies focused solely on the comparison of efficacy 
of the two drugs while others, only on complications arising after 
hemostasis was achieved [3]. Therefore, the study has been designed 
with the aim to compare both the efficacy and safety of terlipressin 
and octreotide in the management of acute variceal bleed. In this 
regard, it would be first of analysis to compare and contrast two 
commonly used pharmacological approaches with regard to the 
risks involved as well as benefits observed.
METHODS
Data source
Studies were identified using an electronic database such as MEDLINE, 
PubMed search engine, and Cochrane clinical trial register.
Randomized controlled trials (RCTs) comparing terlipressin and 
octreotide in patients with acute upper gastrointestinal variceal 
bleeding were included in the study. The use of endoscopy, either for 
diagnostic or therapeutic purposes, was permitted as long as both the 
groups were treated equally. The database was searched for the studies 
with inclusion criteria from 1994 to 2019. Our search was limited to 
RCTs only.
The primary outcome of interest was to determine the efficacy of the 
agent to control active bleeding. The secondary outcomes included 
rebleeding on the 5th day and overall mortality during the study period. 
Complications occurring due to therapy were also analyzed.
Statistical analysis
Two investigators independently assessed each study to determine 
eligibility. The discrepancy was sought using Cohen’s kappa statistic. 
Quality of clinical trials was assessed on the basis of method of the 
randomization, allocation concealment, and blinding [5].
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Review Manager Software Version 5.3 was used to conduct meta-
analysis using a fixed-effect model [6]. For dichotomous data, odds 
ratio (OR) with 95% CI was used. I2 statistic was used to determine 
statistical heterogeneity. The I2 value of <25%, 25–50%, and >50% 
were considered as low, moderate, and high heterogeneity, respectively.
RESULTS
We screened 59 citations, and six were selected for full-text retrieval. 
All six studies met our inclusion criteria (Fig. 1).
All six studies had adequate randomization involving methods such as 
computer-generated random numbers or use of random number tables. 
Of six studies, three had adequate allocation concealment; two were 
double blind and one single blind.
A total of 1129 study participants in six trials comparing terlipressin 
with octreotide were included in the study. The mean age of participants 
was 49.7±6.8 years. The study characteristics of the studies are shown 
in Table 1.
Figure 2 shows the forest plot comparison of the initial hemostasis rate 
of the two groups, terlipressin, and octreotide in acute variceal bleed. 
The fixed-effects model showed a trend toward terlipressin with OR of 
0.96 (95% CI: 0.66–1.42; p=0.86). However, this result was statistically 
not significant. There was moderate heterogeneity noted among the 
studies evidenced by I2 of 36%.
The risk of rebleeding during the hospital stay was not found to be 
statistically significant (OR= 0.75, 95% CI: 0.51–1.10; p=0.14; I2=52%), 
as shown in Fig. 3. One of the trials reported zero incidences of 
rebleeding in both the comparator groups.
There was no statistical evidence of a difference in all-cause mortality 
at 42 days (OR=0.98, 95% CI: 0.66–1.47; p=0.93) (Fig. 4). Remarkably, 
no heterogeneity was noted among the studies, as evidenced by I2=0.
There were no serious adverse events reported in any of the trials. The 
most common adverse event reported in both the treatment groups in all 
the studies was hyponatremia. Other adverse reactions reported were mild 
and mostly related to gastrointestinal system. Two of six trials with 581 
participants contributed to the data on safety of terlipressin and octreotide 
in the management of variceal bleeding. There was no statistically 
significant difference in the complications due to therapy with octreotide 
than with terlipressin (OR=2.05, 95% CI: 0.80–5.76; p=0.10; I2=64%).
DISCUSSION
There was no statistically significant difference observed in the initial 
hemostasis achieved by either terlipressin or octreotide. This finding is 
also supported by other studies [3,10]. However, according to one study, 
terlipressin was found to be significantly less effective in controlling 
bleeding within 24 h as compared to octreotide [11]. However, the 
analysis included only two studies with relatively smaller sample size. 










Records excluded (n=47) 
Duplicate studies and no
comparison of groups
Full text articles assessed
for eligibility (n=11)






Studies included in qualitative
and quantitative synthesis (n=6)
Fig. 1: Inclusion of studies for data analysis
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Recurrent hemorrhage rates did not differ significantly between the 
two drug therapies. The same observation was found in other studies 
as well [3,10]. The risk of rebleeding is very high within 24 h extending 
up to the first 10 days. It parallels the survival rate and hence directly 
influences the outcome of acute variceal bleeding.
Furthermore, no statistically significant difference between overall mortality 
rates was found in the study [3,10]. Survival rates have been improved in 
the past few years due to better quality of care, newer modalities of the 
diagnosis and treatment, and, last but not least, the development of early 
warning scores. However, it is still associated with 15–20% mortality.
The study revealed no statistically significant difference between the 
complications arising due to either therapy. However, data regarding 
safety of the drugs were available in two of the six studies. Theoretically, 
terlipressin is presumed to have lesser ischemic events as compared to 
vasopressin, but the risk is still present. At high doses, hyponatremia 
may occur [12]. On the other hand, octreotide is associated with 
Table 1: Study characteristics
S. No. Study N Dose Duration of treatment (days)
Terlipressin Octreotide Terlipressin Octreotide
1. Abid et al.,[7] 
2009
324 2×10−3 g by IV bolus followed by 
1×10−3 g IV every 6 h
100 μg IV bolus followed by a 
continuous infusion at 50 μg/h
3 3
2. Asad and 
Alam,[2] 2014
80 NM NM NM NM
3. Brunati et al.,[8] 
1996
56 NM NM NM NM
4. Cho et al.,[9] 
2016
88 2×10−3 g IV followed by 1×10−3 g 
every 4 h
Continuous infusion 25 μg/h 3 5
5. Pedretti 
et al.,[10] 1994
60 Day 1:2×10−3 g intravenous bolus 
every 4 h, Day 2:2×10−3 g every 
6 h, Day 3–7:1×10−3 g every 6 h
Day 1:100 μg bolus followed 
by continuous IV infusion at 
25 μg/h; Day 2: 100 μg t.i.d. SC
7 7
6. Seo et al.,[4] 2014 521 2×10−3 g by IV bolus followed by 
1×10−3 g IV every 6 h
50 μg IV bolus followed by a 
continuous infusion at 25 μg/h
5 5
N: Sample size; NM: Not mentioned
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milder gastrointestinal adverse effects. Serious adverse effects are not 
commonly encountered.
It was found that the use of terlipressin was associated with shorter 
hospital stay as compared to octreotide. However, this was a finding 
from a single study and hence cannot be generalized. Further studies 
are required to clarify this issue [4].
In practice, the choice of pharmacological agents is usually based on 
availability and cost. Terlipressin is not available in the United States; 
therefore, octreotide is commonly prescribed as vasopressor to arrest 
bleeding. Affordability to the patient is another important issue to be 
addressed on, especially in developing countries like India. While the 
common regimen of terlipressin is an initial dose of 2 × 10−3 g IV every 
4 h and then titrated down to 1 × 10−3 g IV every 4 h once hemorrhage is 
controlled, octreotide is being prescribed as bolus 50 × 10−6 g IV followed 
by a continuous IV infusion. Discrepancies in the initial doses and the 
duration of therapy have been noted in regimens of various guidelines 
as also evident in this study. The optimal duration of pharmacological 
therapy has not been well established. In RCTs, the duration of vasoactive 
treatment was found to be variable ranging from 3 days to 7 days.
The study has certain limitations. Poor to moderate quality of supporting 
evidence as well as smaller sample size of trials could have influenced 
the results. Few studies did not clearly state if blinding, allocation 
concealment and intention-to-treat analysis was performed. A wide 
range of publication dates (1996–2019) was selected to strengthen 
the analysis. However, standard clinical practices may vary from one 
time period to another contributing to heterogeneity. Nevertheless, 
heterogeneity was found to be low to moderate in our study. In the case 
of overall mortality, it was found to be zero.
CONCLUSION
Terlipressin was found to be non-inferior to octreotide regarding its 
efficacy in controlling the variceal bleed. Moreover, the complications 
and mortality rates did not differ significantly between the two groups. 
Therefore, either of the two drugs can be used in the management of 
acute variceal bleeding. However, firm conclusions cannot be drawn 
due to mentioned limitations. Large RCTs with adequate quality are 
warranted for further research.
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